KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Liabilities: 2009-2025

Historic Total Liabilities for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to $9.2 billion.

  • Regeneron Pharmaceuticals' Total Liabilities rose 13.50% to $9.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 billion, marking a year-over-year increase of 13.50%. This contributed to the annual value of $8.4 billion for FY2024, which is 18.27% up from last year.
  • Regeneron Pharmaceuticals' Total Liabilities amounted to $9.2 billion in Q3 2025, which was up 11.25% from $8.3 billion recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Total Liabilities ranged from a high of $9.2 billion in Q3 2025 and a low of $5.8 billion during Q1 2021.
  • For the 3-year period, Regeneron Pharmaceuticals' Total Liabilities averaged around $7.7 billion, with its median value being $7.9 billion (2024).
  • Its Total Liabilities has fluctuated over the past 5 years, first spiked by 59.89% in 2021, then decreased by 2.72% in 2022.
  • Regeneron Pharmaceuticals' Total Liabilities (Quarterly) stood at $6.7 billion in 2021, then decreased by 1.73% to $6.6 billion in 2022, then climbed by 8.50% to $7.1 billion in 2023, then grew by 18.27% to $8.4 billion in 2024, then grew by 13.50% to $9.2 billion in 2025.
  • Its Total Liabilities was $9.2 billion in Q3 2025, compared to $8.3 billion in Q2 2025 and $8.2 billion in Q1 2025.